Debiopharm Signs Agreement With MSM Protein

Debiopharm and MSM Protein (MSM) have sealed an agreement for the development and commercialisation of Debio 0929, to be developed into a new oncology therapeutic drug. Debio 0929 is an antibody targeting a G protein-coupled receptor (GPCR).

Under the terms of the agreement, Debiopharm and MSM have formed a partnership to select antibodies against the GPCR.

Upon completion of the discovery phase, MSM will grant Debiopharm a worldwide exclusive licence for the development and commercialisation of the antibody.

Reportedly, MSM will retain the marketing rights for Russia, Ukraine and several other countries in Eastern Europe and Asia. MSM will also receive milestone payments from Debiopharm during the development of the product, as well as a share of royalties on net sales.

Tajib Mirzabekov, president and CEO of MSM, said: This is a very exciting transaction for MSM. We are working with a great partner, on a very exciting and valuable target and we have the chance to launch what may be the first novel biologic in Russia through our Russian subsidiary, Meprotek. It provides a substantial validation for our technology and our team to work with a company of Debiopharm’s caliber. There is a great need in targeting of GPCRs with functionally active, high quality and potent human monoclonal antibodies.